Board of Directors
George M. Milne, Jr., Ph.D.
Chairman of the Board
George Milne has over 30 years of experience in pharmaceutical research and product development. He joined Pfizer in 1970 and held a variety of positions conducting both chemistry and pharmacology research. George became director of the department of immunology and infectious diseases at Pfizer in 1981, was its executive director from 1984 to 1985, and was Vice President of Research and Development from 1985 to 1988. He was appointed Senior Vice President in 1988. In 1993 he was appointed President of Pfizer Central Research and a Senior Vice President of Pfizer with global responsibility for human and veterinary medicine R&D. George has served on multiple corporate boards including Mettler-Toledo, Inc., MedImmune, Athersys, Biostorage Technologies, Aspreva, and Conor Medsystems. George received his BSc in chemistry from Yale University and his Ph.D. in Organic Chemistry from MIT.
Daniel Billen, Ph.D.
Daniel Billen has over 40 years of experience in commercialization of pharmaceutical and biotech products both in Europe and North America. He started with Janssen in their Belgian headquarters in cardiovascular global marketing in 1979. Daniel became head of marketing and sales for Janssen’s newly formed affiliate in Canada in 1983 launching multiple products into the Canadian market. In 1991, Daniel moved over to Amgen to lead its Canadian operations as their first General Manager. He moved to Amgen’s headquarters in California in 2011 where he led the U.S. commercial operations business unit and later the combined nephrology and inflammation business unit as their VP/GM. In 2017, Daniel took on the role of Vice President of Global Commercial Initiatives with focus on the evolving U.S. payer landscape. Daniel received his Ph.D. in chemistry from the University of Louvain in Belgium.
R. Hector MacKay-Dunn, J.D., Q.C.
Hector MacKay-Dunn has over 30 years of experience providing legal advice to high-growth public and private companies, many of which achieving valuations exceeding $ billion over a broad range of industry sectors including life sciences, health, and technology. He has experience advising on corporate domestic and cross-border public and private securities offerings, mergers and acquisitions, as well as international partnering and licensing transactions and boards of directors and independent board committees on corporate governance matters. Hector is recognized by Lexpert as being among the Top 100 Canada/U.S. Cross-Border Corporate Lawyers in Canada, has consistently been named among The Leading 500 Lawyers in Canada, and is recognized among Canada’s leading lawyers in mergers & acquisitions, technology, and biotechnology. Hector received the Queen’s Counsel designation upon recommendation by the Attorney General of British Columbia for exceptional merit and contribution to the legal profession, the “AV Preeminent 5.0 out of 5” legal ability rating from Martindale-Hubbell, and is regularly recognized as a leading lawyer nationally by Chambers Canada within the life sciences category. Hector has served as board member or officer with Aspreva Pharmaceuticals Corporation, Arbutus Biophara Corp., XBiotech Inc., MedGenesis Therapeutix Inc., and QLT Inc., is a board member of the BC (British Columbia) Tech Association, previously Board Chair of the Innovation Council of British Columbia, and board member of LifeSciences British Columbia and Genome British Columbia.
Chief Executive Officer, Director
Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board of Directors of Aurinia. From March 2018 to April 2019, Peter served as the Chief Executive Officer of Cerecor, Inc. He remains on the Board of Directors of Cerecor, Inc., where he has served as a member since May 2017. From March 2014 to February 2018, Peter served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP). Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to UK pharmaceutical company Mallinckrodt PLC. From June 2013 to March 2014, Peter served as CEO and a member of the Board of Directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, he was employed by Medlmmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Peter also served as President of Medlmmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of Medlmmune, Peter was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development, and strategy functions. He has also held senior commercial roles at Centocor, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. Peter currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of Invest Maryland, a public-private partnership to spur venture capital investment in the state. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI). Peter earned an MBA from St. Joseph's University and a B.S. from Western Connecticut State University.
Peter’s significant executive management, leadership, corporate development, and commercial operations experience in the biopharmaceutical industry enables him to provide valuable insight to our Board of Directors.
Joseph P. Hagan
Joseph P. "Jay" Hagan is President and Chief Executive Officer of Regulus Therapeutics. Joseph joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer, and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Joseph’s career includes roles as the Executive Vice President, Chief Financial Officer, and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director of Amgen Ventures and Head of Corporate Development for Amgen Inc. Joseph has led numerous strategic and financing transactions including the acquisitions of Immunex and Tularik and the spinout of Novantrone and Relyspa, as well as many other business development efforts totaling over $15 billion in value. Before joining Amgen, Joseph spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. Joseph currently serves on the Board of Directors of Zosano Pharma, a publicly traded biotechnology company. He received an MBA from Northeastern University and a B.S. in physiology and neuroscience from the University of California, San Diego.
Michael Hayden, C.M., OBC, MB, ChB, Ph.D., FRCP (C), FRSC
Michael Hayden was recently named one of the 50 Canadians born in the 20th century who have changed the world. He is the Co-Founder of three biotechnology companies: NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., and Aspreva Pharmaceuticals Corp. Michael sits on different boards including Xenon Pharmaceuticals and Lycera and is author of over 860 peer-reviewed publications and invited submissions. Michael has focused his research primarily on genetic diseases, including genetics of diabetes, lipoprotein disorders, Huntington disease, predictive, and personalized medicine. Michael was inducted into the Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice’s “100 of the Most Inspiring People” (2015); awarded an Honorary Doctor of Science by the University of Gottingen (2014), the Luminary award by the Personalized Medicine World Conference (2014), and the Diamond Jubilee Medal (2012), on behalf of HRH Queen Elisabeth II, in recognition of his significant contributions and achievements. Michael has also been awarded the Order of Canada (2011) and the Order of British Columbia (2010). He was named Canada’s Health Researcher of the Year by CIHR (NIH of Canada) in 2008 and he received the Prix Galien in 2007, which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research.
David R.W. Jayne, M.D., FRCP, FRCPE, FMedSci
David Jayne is Professor of Clinical Autoimmunity in Department of Medicine at the University of Cambridge, UK. David received his B.S. in surgery and medicine from Cambridge University, Cambridge, UK. He received postgraduate training at several London hospitals and Harvard University. He is a fellow of the Royal Colleges of Physicians of London and Edinburgh, and the Academy of Medical Science. He is a certified nephrologist and an Honorary Consultant Physician at Addenbrooke’s Hospital, Cambridge UK. David is a medical advisor to UK, U.S. and EU regulatory bodies, patient groups, and professional organizations. He has published more than 250 peer-reviewed journal articles, book chapters, and reviews. He was elected the first President of the European Vasculitis Society in 2011 and is a member of the ERA-EDTA immunopathology working group. David’s research includes investigator-initiated international trials and the introduction of newer therapies in vasculitis and SLE with collaborators on five continents.
Jill Leversage was appointed as an Independent Director of Aurinia in November 2019. Jill began her finance career at Burns Fry Ltd. and has held senior level positions at BMO Financial Group, RBC Capital Markets, and TD Securities. Jill has served on a number of public and not-for-profit corporate boards including MAG Silver Corp, RE Royalty Ltd., Insurance Corporate of BC, CMAIO, and the Vancouver Airport Authority. Jill is a Fellow of the Institute of Chartered Professional Accountants of British Columbia and also a Chartered Business Valuator (ret.) of the Canadian Institute of Chartered Business Valuators.
Timothy P. Walbert
Mr. Walbert has nearly 30 years of experience commercializing pharmaceutical products. Mr. Walbert is currently chairman, president and chief executive officer of Horizon Therapeutics plc. He also served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda. Prior to IDM, Mr. Walbert was the executive vice president of commercial operations at NeoPharm, Inc. Prior to this he was the divisional vice president and general manager, immunology, at Abbott where he led the global development and launch of HUMIRA. Mr. Walbert also served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Earlier in his career, he held sales and marketing roles with increasing responsibility at several multinational pharmaceutical companies including G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, Pa.